HC Wainwright & Co. Maintains Buy on BriaCell Therapeutics, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar maintains a 'Buy' rating on BriaCell Therapeutics (NASDAQ:BCTX) but lowers the price target from $25 to $20.

October 03, 2023 | 4:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BriaCell Therapeutics' price target has been lowered from $25 to $20 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100